Annual report [Section 13 and 15(d), not S-K Item 405]

Royalty and Commercial Payment Purchase Agreements - Cost Recovery Method - LadRx (Details)

v3.26.1
Royalty and Commercial Payment Purchase Agreements - Cost Recovery Method - LadRx (Details) - USD ($)
$ in Thousands
1 Months Ended 12 Months Ended
Jun. 21, 2023
Jun. 30, 2024
Dec. 31, 2025
Dec. 31, 2024
Agreements        
Contingent consideration under RPAs, AAAs, and CPPAs     $ 0 $ 3,000
Payments of consideration under RPAs, AAAs and CPPAs     8,000 53,000
Long-term royalty and commercial payment receivables under the cost recovery method     55,888 55,936
Receipts under RPAs, AAAs, and CPPAs     3,300 29,248
Short-term royalty and commercial payment receivables under the cost recovery method     0 413
LadRx | Assignment and Assumption Agreement and Royalty Purchase Agreement        
Agreements        
Amount of regulatory milestone payment removed   $ 4,000    
Payments of consideration under RPAs, AAAs and CPPAs $ 5,000      
Maximum regulatory and commercial sales milestone payments 6,000      
Maximum regulatory milestone payments 5,000      
Maximum commercial sales milestone payments 1,000      
Long-term royalty and commercial payment receivables under the cost recovery method 6,000      
Receipts under RPAs, AAAs, and CPPAs     2,900  
Allowance for credit losses     $ 0 0
LadRx | Assignment and Assumption Agreement and Royalty Purchase Agreement | Regulatory milestones        
Agreements        
Contingent consideration under RPAs, AAAs, and CPPAs $ 1,000      
Payments of consideration under RPAs, AAAs and CPPAs       1,000
LadRx | Assignment and Assumption Agreement and Royalty Purchase Agreement | Sales-based milestones        
Agreements        
Payments of consideration under RPAs, AAAs and CPPAs       $ 1,000
LadRx | Assignment and Assumption Agreement and Royalty Purchase Agreement | Aldoxorubicin | Regulatory milestones        
Agreements        
Contingent consideration under RPAs, AAAs, and CPPAs   $ 0